Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

NIO Q1 Sales $1.56B Beat $1.49B Estimate

NIO (NYSE:NIO) reported quarterly sales of $1.56 billion which beat the analyst consensus estimate of $1.49 billion by 4.90 percent. This is a 28.33 percent increase over sales of $1.22 billion the same period last
byBenzinga Newsdesk
June 9, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

NIO (NYSE:NIO) reported quarterly sales of $1.56 billion which beat the analyst consensus estimate of $1.49 billion by 4.90 percent. This is a 28.33 percent increase over sales of $1.22 billion the same period last year.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Mesoblast Announced Single Intervention With Rexlemestrocel-l Improves Left Ventricular Ejection Fraction at 12 Months, Preceding Long-term Reduction in Major Adverse Cardiovascular Events

By Charles Gross
Today, 10:30 AM
Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that treatment of HFrEF patients with rexlemestrocel-L, its allogeneic "off-the-shelf" product candidate for the treatment of chronic heart failure with reduced ejection fraction, resulted in greater improvement in the pre-specified analysis of left ventricular ejecti

MESO